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ABSTRACT
Nanoparticles have presented a new paradigm in anticancer drug delivery to reduce adverse effects and
improve therapeutic outcomes. Nanoparticle surface properties and morphology significantly affect the drug
delivery to tumors while passive targeting. Conjugations with hyaluronic acid, transferrin and aptamers have
shown to be effective in active targeting of anticancer drugs to tumor tissues. This review presents an overview of
some credible techniques of passive and active drug delivery to tumors.
KEY WORDS: Nanoparticle, cancer, targeting, hyaluronic acid, transferrin, aptamer.
INTRODUCTION
Rigid nanoparticles are solid colloidal particles in size
less than 1µm, in which the active principle (drug or
biologically active material) is dissolved, entrapped,
encapsulated and/or to which the active principle is
adsorbed or conjugated to the surface.[1] Some scientists
restrict the definition to structures with a size range of 1–
100 nm in at least one dimension.[2] Two major types of
particulate systems are used in nanomedicines, 1) drug
molecules dispersed within a dense polymeric/lipid
matrix, or 2) drug molecules dissolved in a liquid
core or in a lipid or polymer micelles or vesicles.
Various colloidal drug carrier systems like liposomes,
niosomes and microemulsions which are similar to
polymeric nanoparticles with respect to their shape, size
and mode of administration, have been employed as an
alternative to nanoparticles. However, the rigid
nanoparticles offer additional advantages when compared
to the other colloidal carriers, such as easier terminal
sterilization, higher stability during storage and invivo, easy dispersion of lyophilized products for
administration, protection of the drug against
degradation due to encapsulation of the drug in the solid
polymer matrix and modulation of the drug release
profile by changing the polymer composition.[3,4,5]
Over the last decade, the biodegradable nanoparticles
have gained enormous interest for cancer therapy. The
polymeric biodegradable nanoparticles have been
largely investigated for the purpose of controlled and/or
targeted drug delivery. Biodegradable polymers are
typically degraded into individual monomers, which
are metabolized and removed from the body via
normal metabolic pathways. A number of different
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polymers have been utilized in preparation of
nanoparticles, but poly(lactide) (PLA) and poly(lactideco-glycolide) (PLGA) have been the most popular
ones.[6] PLA and PLGA are biocompatible and
biodegradable and thus, they pose a minimal risk of
toxic side effects in-vivo. The corona of the polymeric
nanoparticle acts like a shielding layer to protect the
encapsulated drug from plasma proteins in-vivo, while
the targeting ligand facilitates the delivery of
nanoparticles to the target site.
Nanoparticle size and shape
Since a number of anticancer drugs have a short half-life
following administration due to their low molecular
weights, hydrophobicity and degradability[7], it is
important to study the effect of particle size and shape
on
the overall circulation time. Parenteral
administration of the nanoparticles necessitates their
size to be as small as possible in order to be able to
reach the targeted destination especially since the inner
diameter of the smallest capillaries in human body can be
as minute as 4 µm.[8] Furthermore, the nanoparticles
exhibit the "EPR (Enhanced Permeation and Retention)
effect" due to the leaky tumor vasculature and poorly
developed lymph system in tumors.[9] For the EPR effect
to occur, it is desirable that nanoparticles be as small as
possible. The lower limit for the nanoparticle size is set at
10 nm, to avoid the renal clearance, as the threshold
diameter for the glomerular filtration is considered to be
in the range of 8-10nm.[10]
A number of studies indicate that the nanoparticle
shape could significantly affect their circulation time.[11]
It was shown that the filamentous micelles as long as
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18 µM could have a circulation half-life of almost twice
that of the spherical particles.[12] It was reported that
interaction of the nanoparticles with the macrophages
and contact angle formed could be responsible for
shape effect on the circulation time.[13]
Nanoparticle surface properties
Nanoparticles have high surface-to-volume ratios when
compared to larger particles. Therefore, control of their
surface properties is crucial to their in-vivo behavior.
Intravenous administration of polymeric nanoparticles
or conventional colloidal carriers, leads to their rapid
removal from the blood circulation by the macrophages
of the Mononuclear Phagocyte System (MPS), also
known as Reticuloendothelial System (RES). Within
seconds of introduction of nanoparticles in the
bloodstream, plasma proteins called opsonins adsorb
on the surface of nanoparticles and render them
'visible' to the macrophages, mainly the Kupffer cells
or macrophages of the liver, which ultimately
phagocytize them. Thus, the nanoparticles are removed
from the bloodstream even before reaching their target site
of action, making them totally ineffective.[14,15] There is
no absolute method to completely inhibit this process of
opsonization and phagocytosis of nanoparticles, but there
are ways to slow it down.
Typically, it has been observed that plasma proteins
are attracted more towards the hydrophobic surface as
compared for hydrophilic surface. Also, research has
shown a correlation between surface charge and
opsonization, with the charged particles having higher
chances of being opsonized than the neutral ones.[16] A
widely used method to prevent opsonization is to shield
the surface of nanoparticles by use of long hydrophilic
polymer chains that can protect the charged and/or
hydrophobic nanoparticles from being recognized by
the plasma proteins. Examples of such polymers are:
polysaccharides, polyacrylamide, poly(vinyl alcohol),
poly(vinyl-2- pyrrolidone), PEG and PEG-containing
copolymers. However, the most popular and commonly
used polymer are PEG and PEG-containing copolymers
and the method of decorating a particle surface by
covalently grafting, entrapping or adsorbing PEG
chains onto the surface is called PEGylation.[17]
Targeting tumor microenvironment
A major advantage of nanoparticles is their drug targeting
potential, which has been widely studied in the field of
cancer therapy.[18,19,20] Nanoparticles have the ability to
passively target the chemotherapeutic drug to the tumor
site by exploiting the tumor blood vessel
characteristics. This ability to passively targeting of the
drug could be due to the combination of EPR effect and
passive diffusion. Additionally, the surface of
nanoparticles can be conjugated to various targeting
moieties such as antibodies, aptamers to achieve active
targeting of the drug.
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Passive Targeting: To satisfy the increased nutrition
need of the multiplying tumor cells, there is rapid
angiogenesis (formation of new blood vessels) in the
tumor, which results in aberrant tortuosity and
abnormalities in the basement membrane of newly
formed tumor blood vessels. Thus, the incomplete tumor
vasculature demonstrates porous blood vessels with gap
size ranging from 100-700 nm depending on tumor type,
allowing the entry of nanoparticles smaller than those
gaps into the tumor interstitium. Moreover, the tumor
lymphatic system is also poorly developed, resulting in
ﬂuid retention in tumors and high interstitial pressure at
the center of tumors than at the periphery.[21] This causes
the retention of the nanoparticles that gain entry into the
tumor interstitium, since these particles are not readily
extravasated into the lymphatic system. Hence, the
combined phenomenon of entry into the tumor
interstitium along with being entrapped in the tumor is
termed as EPR effect. Therefore, many factors
influence the EPR effect; 1) regional blood flow to the
tumor, 2) permeability of the tumor vasculature, 3)
structural barriers imposed by perivascular tumor cells
and extracellular matrix, and 4) intratumoral pressure.[22]
Active Targeting: One of the major challenges in
cancer chemotherapy today, is the targeted delivery of
the therapeutic agent to the desired tumor growth site
avoiding damage to the healthy organs. Active targeting
involves peripheral conjugation of a targeting moiety, that
will specifically bind to the tumor cells, to the surface
of nanoparticles. Thus, the targeted nanoparticles, post
intravenous administration, can reach the tumor site and
selectively bind the tumor cells, leading to the reduction
of chemotherapeutic side effects.
Following are some of the examples of the various
ways in nanoparticles have been utilized to target drugs
to cancer cells:
Hyaluronic Acid: Activated hyaluronic acid (HA)
receptors CD44 and RHAMM are overexpressed on the
tumor cells[23] and thus HA-anchored PLGA
nanoparticulate carriers encapsulating doxorubicin were
prepared which can bind to HA receptors and get
internalized into the tumor cells, ultimately resulting in
targeted drug delivery to the tumor cells. In this case,
HA is linked to PLGA by a diamine PEG spacer and their
targeted delivery would lead to increased exogenous
concentrations of HA assumed to be involved in the
inhibition of tumor metastasis. Thus, the HA-PEGPLGA nanoparticles were able to deliver high
concentrations of doxorubicin to the tumor as compared
with monomethoxy (polyethylene glycol) (mPEG)-PLGA
which reduced the tumor volume significantly after IV
injection in the Ehrlich ascites tumor-bearing mice.[24]
Transferrin:
Transferrin
receptors
(TfR)
are
overexpressed in tumor tissues as compared to the
normal tissues and thus transferrin, a glycoprotein, can
be utilized as a ligand for drug targeting to tumor.[25,26]
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Conjugation of the amine group of Transferrin to the
hydroxyl group of PLGA nanoparticles encapsulating
the chemotherapeutic drug Paclitaxel, via the epoxy
linker facilitates the transcytosis of the carrier system.[27]
Transferrin has also been shown to overcome multi-drug
resistance due to P-gp[28,29] which is overexpressed on
the tumor cell membrane and known to limit the
intracellular uptake of anticancer drugs thereby
decreasing their therapeutic efficacy.[30] Thus, delivery
of
Transferrin
conjugated
paclitaxel
loaded
nanoparticles causes high and sustained intracellular
drug levels as well as increase the antiproliferative action
of the drug as compared to that of the unconjugated
nanoparticles.
Aptamers: Farokhzad and Langer labs have successfully
shown the delivery of aptamer conjugated polymeric
nanoparticles to tumor cells for imaging as well as drug
delivery purposes. They covalently linked a 5' amine
terminated A10 RNA aptamer that binds to PSMA
over expressed on the prostate tumor cells, to PLGAPEG nanoparticles showing desirable size and drug
loading. The conjugation was carried out using the
carbodiimide chemistry in which the terminal carboxyl
group of the polymer reacts with the 5' amine group
of aptamer forming an amide linkage. These
functionalized nanoparticles displayed active binding
and cell uptake in-vitro as well as enhanced nanoparticle
delivery to the prostate tumors in-vivo as compared to the
equivalent
non-functionalized
nanoparticles.
As
reported in their study, the drug loaded nanoparticleaptamer conjugate showed about 20% decrease in cell
viability as compared to the drug nanoparticles alone.
Whereas, the in vivo results obtained in mice,
supported the in vitro results by confirming the
superiority of nanoparticle-aptamer conjugate in
targeting the tumor site.[31] Another study from the
Farokhzad and Langer labs, have shown the use of PSMA
targeted aptamer-nanoparticle conjugate to also deliver
cisplatin to prostate cancer cells.
SUMMARY
Nanoparticles, owing to their characteristics and
advantages, are being used extensively to study their
potential in delivering various drugs/proteins. Their
ability to show passive targeting as well as active
targeting make them an attractive drug delivery approach
especially in diseases like cancer where drug targeting is
essential.
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